Valence ロゴ
人気
ログイン
Loading data for TLSIW — first visit, this takes a few seconds.

ウォッチリストに追加

TriSalus Life Sciences In...

NasdaqGM: TLSIW · リアルタイム株価 · USD
0.56
n/a (n/a)
終値時点： Aug 14, 2026, 3:25 PM

株価、主要な数字、最新ニュースをひとまとめにしたページです。

TriSalus Life Sciences Inc.（TLSIW）の株価・分析・データ

データがありません

買気配n/a
時価総額n/a
売上高（TTM）45.08M
純利益（TTM）-57.25M
0.43
n/a
n/a
n/a
PBR（TTM）2.68
PSR（TTM）n/a
決算発表日n/a
売気配n/a
出来高2
平均出来高（20日）3,979
始値1.11
前日終値n/a
当日レンジ0.56 - 0.56
52週レンジ0.44 - 2.19
アナリストn/a
目標株価n/a
配当n/a
権利落ち日n/a

TLSIWについて

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures...

[続きを読む]
業種
セクター
IPO日 Feb 9, 2021
従業員数 102
上場取引所 NasdaqGM
ティッカー TLSIW
ウェブサイト https://trisaluslifesci.com
企業情報の全文

業績

2025年のTriSalus Life Sciencesの売上高は45.15Mで、前年の29.43Mから53.41%の増加でした。 利益は-39.23Mで、30.56%の増加でした。

財務諸表
news image

3日前 · MarketBeat

TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference

TriSalus Life Sciences (NASDAQ:TLSI) outlined its commercial expansion, product pipeline and clinical-evidence strategy during Canaccord Genuity’s Global Growth Conference, with management emphasizing...

news image

2週間前 · MarketBeat

TriSalus Life Sciences Q2 Earnings Call Highlights

TriSalus Life Sciences (NASDAQ:TLSI) reported second-quarter revenue of $11.4 million, up 1.7% from $11.2 million a year earlier, as demand for its TriNav pressure-enabled drug delivery system increas...

news image

2週間前 · GuruFocus.com

TriSalus Life Sciences Inc (TLSI) (Q2 2026) Earnings Call Highlights: New CMS G-code Expands ...

TriSalus Life Sciences Inc (TLSI) reiterates full-year guidance as reimbursement breakthrough in office-based labs and robust clinical pipeline position the company for accelerated back-half growth.

news image

3か月前 · GuruFocus.com

TriSalus Life Sciences Inc (TLSI) Q1 2026 Earnings Call Highlights: Strategic Expansion and ...

TriSalus Life Sciences Inc (TLSI) navigates commercial growth and FDA delays while showcasing improved margins and robust clinical data.

news image

3か月前 · MarketBeat

TriSalus Life Sciences Q1 Earnings Call Highlights

TriSalus Life Sciences (NASDAQ:TLSI) reported slightly lower first-quarter revenue and reduced its full-year 2026 revenue outlook, citing disruption from a broad commercial reorganization and a delaye...

2ページ中1ページ